Tropical and vector-borne diseases account for more than 17% of all infectious diseases, causing more than 1 million deaths annually. Recognizing infected patients early in their clinical course is critical to researchers working in developing tools to prevent outbreaks. Meridian offer a range of antigens and antibodies suitable for the development of sensitive and specific immunoassays that detect tropical and vector-borne diseases. Their antibody pairs have already been validated in various immunoassays. You won’t waste time finding the right match, it has already been validated for you.

In the first part of this post, I’d like to introduce a selection of ready-to-use antibody pairs available for the main tropical and vector-borne diseases such as Chikungunya, Dengue, Ebola, Leishmania, Malaria, Yellow fever and Zika to name but a few. I’ll focus in the second part on Flavivirus immunoassay development with troubleshooting and usage tips coming from Meridian scientists to help overcoming high epitope cross-reactivity, a common issue in this specific virus family.

Dengue Virus (DenV) is transmitted by mosquito vectors. It infects 50-100 million people each year and is at the origin of Dengue Fever and the more lethal Dengue Hemorrhagic Fever (DHF) and Shock Syndrome (DSS) leading to an estimated 500,000 cases of DHF and 22 000 deaths. The World Health Organization (WHO) estimates that 40% of the world’s population is at risk of infection. In the June issue of Journal of Biomolecular Screening, investigators at San Diego State University (Dept of Biology) and Institute Pasteur Korea (Seoul, South Korea) developed a multiplexed cell-based assay for the identification of modulators of pre-membrane processing as a target for the discovery of DenV inhibitors. (1) The DenV pre-membrane protein (prM) is an essential chaperone for the viral envelope protein which prevents premature fusion with vesicles during viral export. Inhibition of pre-membrane protein cleavage restricts fusion and represents, thus, a novel druggable target. The new in vitro assay developed in this study, is the first described cell-based assay that monitors DenVprM processing within the classical secretory pathway. In a pilot screen of 1,280 small molecules on that assay, Thiostrepton, a known cyclopeptide Antibiotic and FOXM1 inhibitor,  was identified as a novel positive hit in this assay (IC50=4.94 µM). The utility of this novel assay has been proven by the identification of Thiostrepton (available at Focus Biomolecules cat. nr 10-2108) which may be a novel lead compound for the discovery of new drugs effective against Dengue Virus.   1- Stolp Z.D. et al. “A Multiplexed Cell-Based Assay for the Identification of Modulators of Pre-Membrane Processing as a Target against Dengue Virus” (2015) J. Biomol. Screen. 20:616-626. DOI: 10.1177/1087057115571247. Related items A selection of Abnova’s primary antibodies and ELISA kits in relation to Dengue Fever is available here. A few examples:  

Dengue Fever	Cat. Nr	Product Name	Application
Antibody for Dengue Virus	157MAB4043	Dengue virus Types 1,2,3,4 monoclonal antibody, clone BDI419	Dot,IF,EIA
Antibodies for Envelope Protein	157MAB8901	Dengue virus E-D3 monoclonal antibody, clone 5j122	ELISA,WB-Re
Antibodies for NS1 protein	157MAB13532	Dengue virus NS1 monoclonal antibody, clone HM026	ELISA,IF,LFIA